Agilent Technologies OneSeq target enrichment for next-generation sequencing

Agilent Technologies has introduced OneSeq, an all-in-one target enrichment product for next-generation sequencing.

The product is designed to detect and analyse copy number variations, loss of heterozygosity and mutations in a single reaction for use in constitutional disease research. Powered by the company’s SureSelect target enrichment platform, the constitutional research panel will help laboratories involved in cytogenetic research save time gathering and analysing complex, multifactorial data.

The product enables researchers to study both disease-associated targets and copy number variants at the same time. The all-in-one NGS assay is claimed to provide more information than single molecular techniques, allowing scientists to streamline their workflow.

Researchers can combine the product with Agilent’s free SureCall software to integrate data analysis of copy number variations, single nucleotide polymorphisms, indels and loss of heterozygosity. This offers a streamlined method of studying multiple DNA changes associated with genetic disorders.

In addition, the online design application SureDesign enables researchers to customise OneSeq by adding any gene panel of interest to the CNV backbone to suit their needs.